Shandong Weigao Orthopaedic Device Co (688161) Fair Value & Analysis
Healthcare · CN · Market cap 8.9B CNY
Fair value as of: Jul 12, 2026
From 24 valuation models · updated 29 days ago
Share price +0.8% over the past month.
A strong business, but screening 33% overvalued on our models.
What matters now
- A high-quality business (quality 75/100), yet the market already pays well above fair value. Quality at a full price, with little margin of safety.
- The price sits above even our optimistic bull case (¥18.47). The favourable scenario is already priced in.
Price vs Fair Value (5 years)
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Jul 12, 2026.
How to read this chart
60‑month range ¥18.52 – ¥102.84 · fair‑value band ¥11.08 – ¥18.47 · the ¥22.16 price screens above the ¥14.78 fair value. Dashed = 300-day average. As of Jul 12, 2026.
Analysis
Shandong Weigao Orthopaedic Device Co (688161) currently trades at ¥22.16, while our model-based Fair Value estimate is ¥14.78, implying the stock looks roughly 33.3% overvalued today. The Quality Score stands at 75/100 (high quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium, the entry price still matters most (evidence: high).
Over the trailing twelve months, Shandong Weigao Orthopaedic Device Co generated revenue of 1.5B CNY at a net margin of 17.1%. Revenue grew 2.1% year over year. It earns a return on equity of 6.4%. The stock trades on a trailing P/E of 34.3. Fundamentals as of Jul 12, 2026
Our scenario range runs from ¥11.08 (bear case) to ¥18.47 (bull case); at ¥22.16, the current price sits above that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades about 40% below its 52-week high and 2% above its 52-week low, currently below its 200-day average. For context, the median of 10 Healthcare peers we cover trades at -22% fair-value upside, at -33%, 688161 screens richer than that median.
Fair Value models
Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.
All 24 models by family
Widest divergence: DCF Models (¥15.14) versus Dividend Discount (¥3.06). Highest evidence: Residual Income (76).
Key figures & financial health
More key figures
Figures from reported company fundamentals · as of Jul 12, 2026. TTM = trailing twelve months.
Quality Score breakdown
Of which business quality 74 · Market factors (momentum, volatility) 31
Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.
About the company
Shandong Weigao Orthopaedic Device Co., Ltd. engages in research, development, production, and sales of orthopedic medical devices. The company offers orthopedic implantable medical devices and orthopedic surgical instruments.
Full company description
Shandong Weigao Orthopaedic Device Co., Ltd. engages in research, development, production, and sales of orthopedic medical devices. The company offers orthopedic implantable medical devices and orthopedic surgical instruments. It also provides spinal products, such as internal fixation systems for the cervical and thoracic/lumbar spine, and interbody fusion devices; trauma-related products include locking plate systems, intramedullary nail systems, hollow screw systems, and external fixation systems; and joint products, including hip joint prosthesis systems, knee joint prosthesis systems, and shoulder joint prosthesis systems. In addition, the company sports medicine products comprise cruciate ligament reconstruction system, meniscus repair system, and sports trauma system; craniofacial surgery products; and orthopedic diagnostic equipment. The company was founded in 2005 and is based in Weihai, China. Shandong Weigao Orthopaedic Device Co., Ltd. operates as a subsidiary of Shandong Weigao Group Medical Polymer Co., Limited.
Company description, as reported by the company or data provider.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
Shandong Weigao Orthopaedic Device Co reported revenue of ¥1.5B in FY2025 versus ¥2.2B in FY2021, a compound −8.3%/yr. Reported net income was ¥269M in FY2025, compounding −21.0%/yr from FY2021.
688161 screens 33% overvalued. Compare with Abbott Laboratories, →
Peer Group
Medical Devices · 351 stocks
How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.
Valuation Multiples vs Medical Devices median · lower = cheaper
Snowflake
Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.
VALUE 0: the price sits above our fair-value range.
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
ESG scores are not available for this stock yet. Values and ESG data are contextual and can differ between providers.
Similar stocks
10 more Medical Devices stocks, each showing price versus our Fair Value estimate (as of Jul 12, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Abbott Laboratories, ABT | $100.68 | $74.79 | -26% |
| Stryker Corporation SYK | $316.44 | $186.28 | -41% |
| Medtronic plc MDT | $83.56 | $65.57 | -22% |
| Boston Scientific Corporation BSX | $43.04 | $38.44 | -11% |
| Edwards Lifesciences Corporation EW | $85.73 | $41.02 | -52% |
| Siemens Healthineers AG SHL | €34.59 | €33.87 | -2% |
| Shenzhen Mindray Bio-Medical Electronics Co 300760 | ¥149.43 | ¥147.63 | -1% |
| Shanghai United Imaging Healthcare Co 688271 | ¥109.00 | ¥43.60 | -60% |
| Demant A/S DEMANT | kr 276.60 | kr 161.17 | -42% |
| Getinge AB GETIB | kr 206.80 | kr 192.14 | -7% |
Compare Shandong Weigao Orthopaedic Device Co with another stock
Price, fair value, quality and upside side by side.
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is Shandong Weigao Orthopaedic Device Co (688161) overvalued or undervalued?
What is the fair value of 688161?
What is the quality score of 688161?
What is the revenue of Shandong Weigao Orthopaedic Device Co (688161)?
What is the net profit margin of 688161?
Does Shandong Weigao Orthopaedic Device Co pay a dividend?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.
Track Shandong Weigao Orthopaedic Device Co and try Pro for 14 days
One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.
Zero risk: nothing is ever charged. After 14 days you decide whether to stay.